ЦЕЛЬ ИССЛЕДОВАНИЯ Комплексная оценка особенностей ангедонии у пациентов с депрессией с учетом их демографических, клинических и личностных характеристик. МАТЕРИАЛ И МЕТОДЫ Кросс-секционное мультицентровое исследование включает 190 пациентов с депрессией (63,7% женщин, средний возраст (Me) 31 (24—46,5) год) с диагнозами депрессивного эпизода (F32) и рекуррентного депрессивного расстройства (F33) по критериям МКБ-10, вне зависимости от стадии (обострения или ремиссии). Оценивались и фиксировались сопутствующие психические расстройства тревожного спектра, пищевого поведения, употребления психоактивных веществ, а также психотические симптомы. Для оценки выраженности ангедонии использовалась шкала оценки ангедонии Снайта—Гамильтона (Snaith-Hamilton Pleasure Scale — SHAPS). РЕЗУЛЬТАТЫ Пациенты с более ранним манифестом депрессии (p=0,037) и историей суицидальных попыток (p=0,001) демонстрировали более высокие уровни ангедонии. Наличие генерализованного тревожного расстройства, панического расстройства, нервной булимии и зависимости от алкоголя у пациентов с текущей депрессией было связано с большей выраженностью ангедонии. Уровень ангедонии имел умеренные положительные корреляции с дименсией избегания опасности (r=0,30; p<0,01) и слабые отрицательные корреляции с дименсиями зависимости от поощрения (r= –0,20; p<0,05) и кооперативности (r= –0,26; p<0,05). Также отмечены слабые положительные корреляции с выраженностью суицидальных идей и суицидального риска (за последний месяц и в течение жизни) и умеренные положительные корреляции с выраженностью суицидного поведения в течение жизни. ЗАКЛЮЧЕНИЕ Представленное исследование подтверждает и расширяет сведения о комплексном характере феномена ангедонии у пациентов с депрессией. Дальнейшие исследования ангедонии могут помочь в клинической практике и стать базисом для поиска новых биомаркеров депрессии.
19 June 2023 in Psychiatry (Moscow) (Psikhiatriya)
Background: Aripiprazole, among other atypical antipsychotics, is recommended as a drug for maintenance therapy in schizophrenia in cases in which the patient is identified as having depressive symptoms. At the same time, depression in schizophrenia is not listed as a separate indication for Aripiprazole, its antidepressant properties are considered only in the recommendations for the treatment of bipolar depression and augmentation of antidepressant therapy in recurrent depressive disorder. There are no works characterizing the efficacy of the drug in depression in patients with schizophrenia, as well as evaluating the spectrum of its antidepressant action in such conditions.Objective of the study: to examine the therapeutic efficacy and safety of Aripiprazole (Zylaxera®) in the augmentation therapy of moderate to severe depressive states in patients with schizophrenia.Patients and methods: the efficacy and safety of Aripiprazole (Zylaxera®) augmentation therapy with 5–20 mg daily dose for 6 weeks was studied in 72 patients aged 18 to 47 years (all women) with depressive states of at least 17 Hamilton Scale scores in remitted schizophrenia, postchizophrenic depression and schizotypal disorder (F20.01 + F32.1–2; F20.04; F21.3–4 + F32.1–2). The HDRS-21, CGI, and UKU scales were used for psychometric assessment.Results: the effectiveness of augmentation of antidepressant therapy with Zylaxera® was revealed in the majority of patients: the rate of responders as evaluated by the HDRS-21 scale (reduction of severity of depressive disorders by 50% or more) was 67.2% and 71.4% for the CGI scale. At the same time, it was established that the group of responders had a certain similarity in terms of psychopathological structure of depressive states.Conclusion: it has been established, that in patients suffering from schizophrenia Zylaxera® has a distinct efficacy in augmentation of antidepressant therapy and has a favorable tolerability profile. The maximum efficacy of the drug within the framework of such use is observed in depressive states with predominance of negative affectivity.
29 September 2022 in Psychiatry (Moscow) (Psikhiatriya)
Background: personalized approach considering the effectiveness and safety of the medication is the main goal of contemporary psychopharmacotherapy. Knowing special characteristics of any given drug allows a practitioner to choose the tactic meeting needs of the particular patient.The aim of this narrative review was to summarize the data about use Brexpiprazole of in pharmacotherapy of different mental disorders.Method: using the keywords “brexpiprazole”, “psychoses”, “treatment” we performed a scientific publications search in PubMed and PsychInfo databases over the last 10 years.Results: brexpiprazole is supposed to resemble such third generation antypsychotics as aripiprazole and cariprazine, lacking their drawbacks. There is a history of using brexpiprazole in schizophrenia and unipolar depression. Pilot studies and clinical cases were presented on the possible perspectives in use of brexpiprazole, such as Alzheimer disease, posttraumatic stress disorder, borderline personality disorder and bipolar affective disorder. On the basis of the reviewed data we conclude that brexpiprazole is effective for cupping and maintenance treatment of schizophrenia, for augmentation in recurrent depressive disorder and is also perspective in other fields of psychiatry. Brexpiprazole has a favorable safety profile with low incidence of metabolic, extrapyramidal and hyperstimulation symptoms.
23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To investigate the structure and severity of basic symptoms in young female patients with endogenous depression. Material and methods. One hundred and nineteen female patients, aged from 16 to 26 years, were examined. Three groups were identified: patients meeting the criteria of high risk of psychosis (51 patients, mean age 18.55±3.84 years), patients not meeting the criteria of high risk of psychosis(48 patients, mean age 20.12±3.84 years), patients with postpsychotic depression (20 patients, mean age 21.8±4.5 years). The main method of the study was the application of COGDIS (Cognitive Distortions) and COPER (Cognitive-perceptual baseline symptoms) criteria. Results. The baseline symptoms criteria were met by 83.3% of depressed patients without psychosis risk symptoms (mean severity score 24.0±14.7), 96% of depressed patients with high psychosis risk symptoms (38.1±15.9 points), and 50% of patients with postpsychotic depression (15.3±12.9 points). COGDIS criteria were met by 62.5% of depressed patients without psychosis risk symptoms (16.2±10.1 points), 68.6% of depressed patients with high psychosis risk symptoms (22.3±9.6 points), and 25% of patients with postpsychotic depression (9.2±8.4 points). The COPER criteria were met by 77.5% of patients with depression without psychosis risk symptoms (16.2±10.3 points), 92.2% of patients with depression at high risk of psychosis (28.4±14.0 points), and 50% of patients with postpsychotic depression (8.9±9.7 points). Conclusions. The group with post schizophrenic depression was characterized by lower basic symptom scale scores and percentage of eligible patients. Basic symptoms were common in a group of young female patients with depression who did not meet high-risk criteria. The score differentiates the high-risk group from the group of patients without risk symptoms.
17 December 2020 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
Cognitive dysfunction is one of the basic symptoms of endogenous depression, gaining much of the researchers’ interest lately. It is observed at the initial stage, at the peak intensity of depressive symptoms and even after their reduction, which leads to the persistence of residual depressive state. Cognitive impairment during the depressive episode can be detected by objective methods (clinical and neuropsychological), and their subjective importance is being revealed by standardized questionnaires. Depressed patients show lower results in executive functions, working memory, reaction speed, verbal learning, immediate and delayed recall subtests of neuropsychological batteries. There are few pharmacological agents (mostly antidepressants) with well-proven procognitive activity in depression. Besides, some new pharmacological and non-pharmacological approaches for treatment of cognitive impairment in depression have appeared lately and are described in literature as promising.
1 November 2025 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY